| Original language | English (US) |
|---|---|
| Pages (from-to) | 140-141 |
| Number of pages | 2 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 13 2020 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JACC: Cardiovascular Interventions, Vol. 13, No. 1, 13.01.2020, p. 140-141.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Facilitating Stent Advancement by Using the Reverse Movahed's Maneuver (Maximal Expiration) During Tortuous Vein Graft Intervention
AU - Xenogiannis, Iosif
AU - Tajti, Peter
AU - Hall, Allison B.
AU - Alaswad, Khaldoon
AU - Rinfret, Stephane
AU - Nicholson, William
AU - Karmpaliotis, Dimitri
AU - Mashayekhi, Kambis
AU - Furkalo, Sergey
AU - Cavalcante, João L.
AU - Burke, M. Nicholas
AU - Brilakis, Emmanouil S.
N1 - Funding Information: Please note: Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; and has served as a consultant (not financial) for Abbott Laboratories. Dr. Rinfret has received speaker and proctorship honoraria from Boston Scientific, Abbott Vascular Canada, Medtronic Canada, and Terumo US. Dr. Nicholson has served as a proctor, consultant, and advisory board member for Abbott Vascular, Boston Scientific, and Medtronic. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Mashayekhi has received consulting/speakers fees from Asahi Intecc, AstraZeneca, Biotronik, Boston Scientific, Cardinal Health, Daiichi-Sankyo, Medtronic, Teleflex, and Terumo. Dr. Cavalcante has received investigator-initiated research grant support from Medtronic; and has served as a consulting/speaker for Siemens. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, the American Heart Association (Associate Editor of Circulation), Amgen, Boston Scientific, the Cardiovascular Innovations Foundation (Board of Directors), Cardiovascular Systems Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, and Teleflex; has received research support from Siemens, and Regeneron; and is a shareholder in MHI Ventures. All other authors have reported they have no relationships relevant to the contents of this paper to disclose.
PY - 2020/1/13
Y1 - 2020/1/13
UR - http://www.scopus.com/inward/record.url?scp=85076866235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076866235&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2019.11.003
DO - 10.1016/j.jcin.2019.11.003
M3 - Letter
C2 - 31918934
AN - SCOPUS:85076866235
SN - 1936-8798
VL - 13
SP - 140
EP - 141
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 1
ER -